Fiche publication
Date publication
décembre 2019
Journal
Bulletin du cancer
Lien Pubmed
Résumé
For young patients with hormone receptor-positive early breast cancer, tamoxifen for at least 5 years is the standard endocrine treatment. Prolonged endocrine treatment over 5 years is recommended for patients with high risk of late relapse. When adjuvant chemotherapy is indicated, prolonged iatrogenic amenorrhea is a strong pronostic factor. WIthout persistant amenorrhea after chemotherapy, it is indicated to associate ovarian suppression to the endocrine treatment. Optimal duration of this induced amenorrhea is unknown.
Mots clés
Adjuvant setting, Amenorrhea, Aménorrhée, Breast cancer, Cancer du sein, Endocrine treatment, Femme jeune, Hormonothérapie, Traitement adjuvant, Young woman
Référence
Bull Cancer. 2019 Dec;106(12S1):S24-S27
